Operator
Welcome to INmune Bio’s Second Quarter 2026 Earnings Name. [Operator Instructions] As a reminder, this convention name is being recorded. A transcript will likely be accessible roughly 24 hours after the decision.
Earlier than we start, please word that aside from statements of historic truth, statements made by administration and responses to questions might represent forward-looking statements throughout the which means of the protected harbor provisions of the Non-public Securities Litigation Reform Act of 1995.
There are a selection of dangers and uncertainties that would trigger precise outcomes to vary materially from these expressed or implied. We encourage you to evaluation the forward-looking statements disclaimer in at this time’s earnings launch and the chance components described within the firm’s filings with the SEC, together with its most up-to-date quarterly report. Ahead-looking statements communicate solely as of the date they’re made and besides as required by regulation, INmune Bio undertakes no obligation to replace them.
It’s now my pleasure to show the decision over to INmune Bio’s Chief Government Officer, David Moss.
David Moss
President, CEO, Treasurer, Secretary & Director
Thanks for becoming a member of INmune Bio’s second quarter convention name. The second quarter and the weeks that adopted had been outlined by execution throughout each of our late-stage platforms. I’ll start with the investor perspective on the progress we have now made. I’ll then flip the decision over to Dr. Mark Lowdell, our Chief Scientific Officer and the inventor of CORDStrom to debate Ebstrocel and
